May 20, 2013 | By Márcio Barra
Seeking Alpha is reporting that Pfizer discountinued a Phase 3 randomized, open-label, two-arm study evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL), for failling to meet the Primary Endpoint.
In the study, inotuzumab ozogamicin was administered once a month in combination with rituximab, and compared with an active comparator arm, bendamustine plus rituximab or gemcitabine plus rituximab.
During a scheduled interim analysis, an independent Data Monitoring Committee concluded that treatment with inotuzumab ozogamicin plus rituximab would not meet the primary objective of improving overall survival when compared to the comparator arm.
Pfizer says that it will continueto review the the drug for other potential indications.